{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.3","upperLimit":"65.4","value":"45.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Cumulative Incidence of grade II-V acute GVHD with relapse or NRM as competing risks","dispersionType":"95% Confidence Interval","groups":[{"description":"Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis\n\nTacrolimus and Thymoglobulin: Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or \"transplant.\" Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours.","id":"OG000","title":"Tacrolimus and Thymoglobulin"}],"paramType":"NUMBER","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"Assessed first 6 months post transplant","title":"Incidence of Acute GVHD","type":"PRIMARY","unitOfMeasure":"percentage of participants"}